Hereditary cancer accounts for nearly 5-10% of all cancers. With early detection through appropriate screening methods and prophylactic measures, the chances of prevention and successful treatment are higher.

The integration of cancer genetics in clinical practice enables physicians to distinguish a proportion of patients that have inherited mutations with increased risk susceptibility to certain cancers. The identification of such germline mutations allows for targeted cancer surveillance and prevention.

PreSENTIA, with an extensive portfolio of 19 hereditary cancer panels, tests for numerous inherited genetic mutations that could cause cancer in the future.

WHAT IS PreSENTIA?

PreSENTIA consists of an extensive portfolio of 19 hereditary cancer panels. The genes selected have been shown to predispose to certain hereditary cancer syndromes (cancer predisposition syndromes), and hereditary cancers.

The patients’ medical family history, their ethnicity, and any physical findings present linked to cancer should always be taken into consideration.

PreSENTIA offers 18 cancer-specific gene panels, and 1 hereditary pan-cancer panel that covers 62 genes and 24 cancer predisposing syndromes associated with hereditary cancer.

PreSENTIA is a new generation test for identifying genetic mutations with cancer susceptibility. It has an extensive portfolio of 19 hereditary cancer panels. Each panel focuses on a specific set of genes that have high susceptibility to cancer predisposing syndromes, that in turn have increased risk of causing cancer.

BENEFITS OF PreSENTIA INCLUDE:

  • Clinically actionable mutations
  • Proven technology
  • Easy-to-interpret results
  • Short turn-around time

The same mutation can cause cancer earlier in some family members than others, or not develop into cancer at all.

WHO IS THIS TEST FOR?

According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have:

  • Family members with cancer in the same side of the family
  • Multiple cancers in the same family member
  • Family members with early cancer onset
  • Family members with rare cancer types
  • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
  • Personal or family history of a hereditary cancer syndrome

The patients’ medical family history, their ethnicity, and any physical findings present linked to cancer should always be taken into consideration.

Additionally, patients already diagnosed with cancer can take PreSENTIA if their family history is suggestive of an inherited genetic change running in their family. PreSENTIA can let them know if their cancer is hereditary, which will help to:

  • Improve disease classification
  • Inform other family members of their risk
  • Enhance clinical management

* Data adapted from: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology and American College of Obstetricians and Gynecologists.

UNIQUE FEATURES

TARGETED TECHNOLOGY

PreSENTIA is based on a novel, target capture enrichment technology that has been validated for its accuracy and precision.

HIGH READ DEPTH

Specifically-designed genetic and bioinformatics methods have been incorporated to ensure high read-depths, raising the sensitivity and specificity of the test.

MULTI-ENGINE ANALYSIS

Proprietary bioinformatics pipelines analyze the sequencing data produced from each sample, increasing the sensitivity and specificity of PreSENTIA

WHY RECOMMEND PreSENTIA TO MY PATIENTS?

Identifying the genetic mutations that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning and avoiding risk factors.

WHAT ARE THE BENEFITS FOR MY PATIENTS?

  • Ability to select a panel that is most suited to them
  • Targeted cancer monitoring to detect cancer early, when treatment is more beneficial
  • Prevention of cancer by prophylactic measures
  • Invaluable information for family members that might carry the same mutation
  • Improved clinical care

HOW DOES PreSENTIA HELP ME?

PreSENTIA gives you helpful insight into the genetic makeup of your patient in an efficient, rapid and comprehensive way.

Receiving information about your patient's risk of developing cancer early allows you to look into the most appropriate prophylactic measures and therapy options.

You can develop a better clinical management plan for your patient and any of their family members who might also be affected.

WHAT CAN I DO TO HELP MY PATIENTS AFTER TAKING PreSENTIA?

  • Recommend screening tests at key interval timepoints for early cancer detection
  • Recommend prophylactic measures
  • Recommend testing for immediate family members who might be at risk

WHAT DOES IT TEST FOR?

HEREDITARY CANCER PANELS

  • BREAST & GYNECOLO­GICAL

    26

    HEREDITARY BREAST/GYNECOLOGICAL CANCER PANEL

    Description

    Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for breast/gynaecological cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member with multiple cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • Personal history of previous malignancies

    No of Genes Tested

    26

    No of related hereditary cancer syndromes

    12

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • DICER 1 syndrome (DICER1)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4

  • BREAST / GYN GUIDELINES - BASED

    19

    HEREDITARY BREAST/GYNECOLOGICAL GUIDELINES-BASED CANCER PANEL

    Description

    Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    19

    No of related hereditary cancer syndromes

    9

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11

    Disorders associated with this panel:

    • Ataxia telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Peutz-Jeghers syndrome (STK11)
    • PTEN Hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D

  • BREAST
    HIGH-RISK

    7

    HEREDITARY BREAST HIGH-RISK CANCER PANEL

    Description

    Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53

    Disorders associated with this panel:

    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Peutz-Jeughers syndrome (STK11)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    PALB2

  • BRCA1 / BRCA2

    2

    HEREDITARY BRCA1 / BRCA2 CANCER PANEL

    Description

    Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers caused by mutations in the BRCA1/BRCA2 genes are those that have:

    • Several family members with cancer in the same side of the family
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    2

    No of related hereditary cancer syndromes

    1

    Genes Tested

    BRCA1, BRCA2

    Disorders associated with this panel:

    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)

  • COLORECTAL

    17

    HEREDITARY COLORECTAL CANCER PANEL

    Description

    Hereditary Colorectal cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • Personal history of previous malignancies

    No of Genes Tested

    17

    No of related hereditary cancer syndromes

    12

    Genes Tested

    APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • PTEN Hamartoma syndrome (PTEN)
    • Peutz-Jeghers syndrome (STK11)
    • Hereditary diffuse gastric syndrome (CDH1)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • Polymerase Proofreading Associated syndrome (POLD1, POLE)
    • Hereditary mixed polyposis syndrome (GREM1)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
    • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)

  • COLORECTAL
    HIGH-RISK

    10

    HEREDITARY COLORECTAL HIGH-RISK CANCER PANEL

    Description

    Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    10

    No of related hereditary cancer syndromes

    6

    Genes Tested

    APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11

    Disorders associated with this panel:

    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)

  • COLORECTAL
    NON-POLYPOSIS

    5

    HEREDITARY COLORECTAL NON-POLYPOSIS CANCER PANEL

    Description

    Hereditary Colorectal Non-Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    5

    No of related hereditary cancer syndromes

    2

    Genes Tested

    EPCAM, MLH1, MSH2, MSH6, PMS2

    Disorders associated with this panel:

    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

  • COLORECTAL POLYPOSIS SYNDROME

    7

    HEREDITARY COLORECTAL POLYPOSIS CANCER PANEL

    Description

    Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary polyposis colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)

  • MYELODYSPLASTIC SYNDROME/LEUKEMIA

    24

    HEREDITARY MYELODYSPLASTIC SYNDROME / LEUKEMIA CANCER PANEL

    Description

    Hereditary Myelodysplastic syndrome / Leukemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:

    • Family history of a hereditary cancer syndrome associated with leukemia
    • Personal history of a hereditary cancer syndrome associated with leukemia
    • An identical twin who developed leukemia in the first year of life
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    24

    No of related hereditary cancer syndromes

    6

    Genes Tested

    ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
    • Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

  • GASTRIC

    14

    HEREDITARY GASTRIC CANCER PANEL

    Description

    Hereditary Gastric cancer panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:

    • Several family members in the same side of the family with gastric cancer
    • Personal or family history of a hereditary cancer syndrome linked to gastric cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    14

    No of related hereditary cancer syndromes

    8

    Genes Tested

    APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Peutz-Jeghers syndrome (STK11)

  • PROSTATE

    15

    HEREDITARY PROSTATE CANCER PANEL

    Description

    Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • Several first-degree family members with prostate cancer
    • Family members diagnosed with prostate cancer at young age
    • Family members diagnosed with other cancer types, including breast, ovarian and pancreatic
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    15

    No of related hereditary cancer syndromes

    6

    Genes Tested

    ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    HOXB13, NBN, PALB2, RAD51D

  • PANCREATIC

    17

    HEREDITARY PANCREATIC CANCER PANEL

    Description

    Hereditary Pancreatic cancer panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:

    • Several family members in the same side of the family with pancreatic cancer
    • First-degree relative who developed pancreatic cancer before the age of 50
    • Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    17

    No of related hereditary cancer syndromes

    10

    Genes Tested

    APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Multiple endocrine neoplasia type 1 (MEN1)
    • Peutz-Jeghers syndrome (STK11)

  • RENAL

    13

    HEREDITARY RENAL CANCER PANEL

    Description

    Hereditary Renal cancer panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary renal cancers are those that have:

    • Family members that have had renal cancer, especially at a young age
    • Family members with renal cancer in both kidneys
    • Family members diagnosed with a hereditary cancer syndrome associated with renal cancer
    • Personal history of a hereditary cancer syndrome associated with renal cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    13

    No of related hereditary cancer syndromes

    7

    Genes Tested

    BAP1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL

    Disorders associated with this panel:

    • BAP1 mutation associated disease (BAP1)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • PTEN hamartoma syndrome (PTEN)
    • Von-Hippel Lindau syndrome (VHL)

  • SKIN (XP-ASSOCIATED)

    9

    HEREDITARY SKIN (XP-ASSOCIATED) CANCER PANEL

    Description

    Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with skin cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    9

    No of related hereditary cancer syndromes

    1

    Genes Tested

    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC

    Disorders associated with this panel:

    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

  • FAMILIAL MELANOMA

    7

    HEREDITARY FAMILIAL MELANOMA CANCER PANEL

    Description

    Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:

    • At least two first-degree family member who have had metastatic melanoma
    • At least one family member has had multiple melanomas
    • Family or personal history of a hereditary cancer syndrome associated with melanoma
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53

    Disorders associated with this panel:

    • BAP1 mutation associated disease (BAP1)
    • Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
    • Li-Fraumeni syndrome (TP53)
    • PTEN hamartoma syndrome (PTEN)
    • Retinoblastoma (RB1)

  • PARAGANGLI­OMA / PHEOCHROMOCYTOMA

    6

    HEREDITARY PARAGANGLIOMA / PHEOCHROMOCYTOMA CANCER PANEL

    Description

    Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    6

    No of related hereditary cancer syndromes

    3

    Genes Tested

    RET, SDHAF2, SDHB, SDHC, SDHD, VHL

    Disorders associated with this panel:

    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
    • Multiple endocrine neoplasia type 2 (RET)
    • Von-Hippel Lindau syndrome (VHL)

  • PARATHYROID

    1

    HEREDITARY PARATHYROID CANCER PANEL

    Description

    Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least two first-degree family member who have had parathyroid tumors
    • A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    1

    No of related hereditary cancer syndromes

    1

    Genes Tested

    MEN1

    Disorders associated with this panel:

    • Multiple endocrine neoplasia type 1 (MEN1)

  • THYROID

    1

    HEREDITARY THYROID CANCER PANEL

    Description

    Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least one first-degree family member who has had thyroid cancer
    • A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    1

    No of related hereditary cancer syndromes

    1

    Genes Tested

    RET

    Disorders associated with this panel:

    • Multiple endocrine neoplasia type 2 (RET)

  • PAN-CANCER

    62

    HEREDITARY PAN-CANCER PANEL

    Description

    Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • Family members with an unusual type of cancer (breast cancer in a male)
    • Personal or family history of a hereditary cancer syndrome
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    62

    No of related hereditary cancer syndromes

    24

    Genes Tested

    APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • BAP1 mutation associated disease (BAP1)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • DICER 1 syndrome (DICER1)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Hereditary mixed polyposis syndrome (GREM1)
    • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Multiple endocrine neoplasia type 1 (MEN1)
    • Multiple endocrine neoplasia type 2 (RET)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)
    • PTEN hamartoma syndrome (PTEN)
    • Retinoblastoma (RB1)
    • Von-Hippel Lindau syndrome (VHL)
    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D

  • HEREDITARY CANCER SYNDROMES

    AD= Autosomal Dominant, AR= Autosomal Recessive, XLR= X-Linked Recessive

    Cancer Predisposing Syndromes & Associated Genes Associated Cancers PreSENTIA Hereditary Cancer Panel
    Li-Fraumeni syndrome (AD)
    TP53     		Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain, Lung, Leukemia
    • 3 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Gastric Cancer Panel
    • Familial Melanoma Cancer Panel
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Li-Fraumeni syndrome 2 (AD)
    CHEK2     		Breast, Sarcoma, Brain
    • 2 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Prostate Cancer Panel
    • Pan-Cancer Panel
    Hereditary breast and ovarian cancer syndrome (AD)
    BRCA1, BRCA2     		Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus
    • 4 Breast / Gynecological Cancer Panels
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Pan-Cancer Panel
    Familial adenomatous polyposis / Attenuated familial adenomatous polyposis syndrome (AD)
    APC     		Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel
    • 3 Colorectal Cancer Panels
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    MUTYH-associated polyposis syndrome (AR)
    MUTYH     		Colorectal
    • Breast / Gynecological Cancer Panel
    • 3 Colorectal Cancer Panels
    • Pan-Cancer Panel
    Lynch syndrome (AD)
    MLH1, MSH2, MSH6, PMS2, EPCAM     		Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal
    • 2 Breast / Gynecological Cancer Panels
    • 3 Colorectal Cancer Panels
    • Gastric Cancer Panel
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    PTEN hamartoma syndrome (AD)
    PTEN     		Breast, Endometrial, Colorectal, Melanoma, Renal
    • 3 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Familial Melanoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Peutz-Jeghers syndrome (AD)
    STK11     		Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic
    • 3 Breast / Gynecological Cancer Panels
    • 3 Colorectal Cancer Panels
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    Juvenile polyposis syndrome (AD)
    SMAD4, BMPR1A     		Colorectal, Gastric, Pancreatic
    • 3 Colorectal Cancer Panel
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    Fanconi anemia syndrome (AR or XLR)
    FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C     		Leukemia, Tumors of the head & neck, Gastrointestinal
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pan-Cancer Panel
    Von-Hippel Lindau syndrome (AD)
    VHL     		Renal, Paragangliomas, Pheochromocytomas
    • Paraganglioma / Pheochromocytoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Retinoblastoma (AD)
    RB1     		Eye & bone
    • Familial Melanoma Cancer Panel
    • Pan-Cancer Panel
    Xeroderma Pigmentosum syndrome (AR)
    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA,XPC     		Non-Melanoma & Melanoma
    • Skin (XP-associated) Cancer Panel
    • Pan-Cancer Panel
    Hereditary melanoma-pancreatic cancer (AD)
    CDKN2A, CDK4     		Melanoma, Pancreatic
    • Familial Melanoma Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    Hereditary diffuse gastric syndrome (AD)
    CDH1     		Gastric & Breast
    • 3 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Gastric Cancer Panel
    • Pan-Cancer Panel
    DICER 1 syndrome (AD)
    DICER1     		Lung, Renal, Ovarian, Thyroid
    • Breast / Gynecological Cancer Panel
    • Pan-Cancer Panel
    Polymerase Proofreading Associated syndrome (AD)
    POLD1, POLE     		Colorectal & Endometrial
    • Breast / Gynecological Cancer Panel
    • 2 Colorectal Cancer Panels
    • Pan-Cancer Panel
    Multiple Endocrine Neoplasia (MEN) syndrome type 1 (AD)
    MEN1     		Parathyroid & Pancreatic
    • Pancreatic Cancer Panel
    • Parathyroid Cancer Panel
    • Pan-Cancer Panel
    Multiple Endocrine Neoplasia (MEN) syndrome type 2 (AD)
    RET     		Thyroid & Pheochromocytoma
    • Paraganglioma / Pheochromocytoma Cancer Panel
    • Thyroid Cancer Panel
    • Pan-Cancer Panel
    BAP1 mutation associated disease (AD)
    BAP1     		Skin, Eye, Renal, Mesothelioma
    • Familial Melanoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Ataxia-telangiectasia syndrome (AR)
    ATM
    (Susceptibility to breast, pancreatic & prostate cancer: AD)     		Leukemia & Lymphoma
    • 2 Breast / Gynecological Cancer Panels
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pan-Cancer Panel
    Hereditary-mixed polyposis syndrome (AR)
    GREM1     		Colorectal
    • Colorectal Cancer Panel
    • Pan-Cancer Panel
    Constitutional mismatch repair syndrome (AR)
    MSH2, MSH6, MLH1, PMS2     		Hematologic malignancies, Brain, Gastrointestinal, Colorectal
    • 2 Breast / Gynecological Cancer Panels
    • 3 Colorectal Cancer Panels
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Renal Cancer Pane
    • Pan-Cancer Panel
    Hereditary Paraganglioma – Pheochromocytoma syndrome (AD)
    SDHAF2, SDHB, SDHC, SDHD     		Renal, Thyroid, Paragangliomas, Pheochromocytomas
    • Paraganglioma / Pheochromocytoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel

HOW TO ADMINISTER PreSENTIA?

  • RECOMMEND THE IDEAL PANEL TO YOUR PATIENT
  • COLLECT A BUCCAL SWAB FROM YOUR PATIENT
  • SEND THE SAMPLE TO OUR LABORATORY
  • THE SAMPLE WILL BE ANALYZED IN OUR LABORATORY
  • RESULTS WILL BE SENT TO YOU WITHIN 2-3 WEEKS

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!